tbuckley/cabot-search huggingface dataset:
Characteristics of H3 K27M-mutant gliomas in adults
Authors: David Meyronet, Maud Esteban-Mader, Charlotte Bonnet, Marie-Odile Joly, Emmanuelle Uro-Coste, Alexandra Amiel-Benouaich, Fabien Forest, Cécilia Rousselot-Denis, Fanny Burel-Vandenbos, Véronique Bourg, Jacques Guyotat, Tanguy Fenouil, Anne Jouvet, Jérôme Honnorat, François Ducray
Journal: Neuro-Oncology (2016)

Diffuse H3 K27M-mutant gliomas occur primarily in children but can also be encountered in adults. The aim of this study was to describe the characteristics of H3 K27M-mutant gliomas in adults. We analyzed the characteristics of 21 adult H3 K27M-mutant gliomas and compared them with those of 135 adult diffuse gliomas without histone H3 and without isocitrate dehydrogenase (IDH) mutation (IDH/H3 wild type). The median age at diagnosis in H3 K27M-mutant gliomas was 32 years (range: 18–82 y). All tumors had a midline location (spinal cord n = 6, thalamus n = 5, brainstem n = 5, cerebellum n = 3, hypothalamus n = 1, and pineal region n = 1) and were IDH and BRAF-V600E wild type. The identification of an H3 K27M mutation significantly impacted the diagnosis in 3 patients (14%) for whom the histological aspect initially suggested a diffuse low-grade glioma and in 7 patients (33%) for whom pathological analysis hesitated between a diffuse glioma, ganglioglioma, or pilocytic astrocytoma. Compared with IDH/H3 wild-type gliomas, H3 K27M-mutant gliomas were diagnosed at an earlier age (32 vs 64 y, P < .001), always had a midline location (21/21 vs 21/130, P < .001), less frequently had a methylated MGMT promoter (1/21 vs 52/129, P = .002), and lacked EGFR amplification (0/21 vs 26/128, P = .02). The median survival was 19.6 months in H3 K27M-mutant gliomas and 17 months in IDH/H3 wild-type gliomas (P = .3). In adults, as in children, H3 K27M mutations define a distinct subgroup of IDH wild-type gliomas characterized by a constant midline location, low rate of MGMT promoter methylation, and poor prognosis.
Molecular profiling of small cell lung cancers in Japanese patients.
Authors: Kazushige Wakuda, Hirotsugu Kenmotsu, Masakuni Serizawa, Yasuhiro Koh, Mitsuhiro Isaka, Toshiaki Takahashi, Haruyasu Murakami, Tateaki Naito, Tetsuhiko Taira, Takehito Shukuya, Akira Ono, Hiroaki Akamatsu, Hisao Imai, Keita Mori, Masahiro Endo, Takashi Nakajima, Yasuhisa Ohde, Nobuyuki Yamamoto
Journal: Journal of Clinical Oncology (2013)

7599 Background: Molecular abnormalities discovered in the last decade have led to a paradigm shift in the diagnosis and treatment of lung adenocarcinoma. But there have been few reports about molecular profiling of small cell lung cancers (SCLC). We conducted the Shizuoka Lung Cancer Mutation Study to analyze driver mutations in patients with thoracic SCLC malignancies. Methods: We collected molecular profiling data of SCLC from the biobanking system in conjunction with the clinic, including the pathology lab, where 23 mutations in 9 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN and HER2), EGFR, MET, PIK3CA, FGFR1 and FGFR2 amplifications, and EML4-ALK translocations were assessed using pyrosequensing plus capillary electrophoresis, qRT-PCR, and RT-PCR, respectively. To evaluate mutation status for SCLC patients, we collected patient characteristics data from medical records. Results: Between July 2011 and July 2012, fifty small cell lung cancer patients were assessed in our biobanking system. Patient characteristics were as follows: median age (range) 70 (43 - 82) years; male 82%; smoker 96%; limited disease/extended disease 56/44%; small cell carcinoma/combined small cell carcinoma with adenocarcinoma 94/6%; surgically resected snap-frozen samples 8, formalin-fixed paraffin-embedded samples 40 and pleural effusion 7. We detected driver mutations in 8 cases (16%). Mutations found: EGFR 1 (2%), KRAS 1 (2%), PIK3CA 2 (4%), AKT1 1 (2%), MET amplification 1 (2%), PIK3CA amplification 6 (12%). EGFR and KRAS mutation were found in combined small cell carcinoma with adenocarcinoma. No significant differences in age, sex, disease extent at diagnosis or smoking status were found between patients with mutations and those without mutations. But serum neuron-specific enolase (NSE) levels were significantly higher in patients without mutations (p=0.03). Conclusions: In our analysis, driver mutations were found in 16% of SCLC patients and PIK3CA amplification seemed to be relatively frequent in SCLC. Our results suggest that PIK3CA might become a target of treatment for SCLC patients.
Effectiveness of Computer Automation for the Diagnosis and Management of Childhood Type 2 Diabetes
Authors: Tamara S. Hannon, Tamara M. Dugan, Chandan K. Saha, Steven J. McKee, Stephen M. Downs, Aaron E. Carroll
Journal: JAMA Pediatrics (2017)

Type 2 diabetes (T2D) is increasingly common in young individuals. Primary prevention and screening among children and adolescents who are at substantial risk for T2D are recommended, but implementation of T2D screening practices in the pediatric primary care setting is uncommon.
Lenalidomide Selectively Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome (MDS) Patients with 5q Deletion.
Authors: Martin Jädersten, Andrea Pellagatti, Ann-Mari Forsblom, Emma K. Emanuelsson, Mats Merup, Jan Samuelsson, James S. Wainscoat, Jacqueline Boultwood, Eva Hellström-Lindberg
Journal: Blood (2005)
Targeting Proteinkinase C Alters ER-Stress and b-Catenin Signaling in Multiple Myeloma: Therapeutic Implications.
Authors: Marc S. Raab, Klaus Podar, Jing Zhang, Giovanni Tonon, Johannes H. Fruehauf, Iris Breitkreutz, Boris K. Lin, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson
Journal: Blood (2007)
A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm+ OvCa)
Authors: J.-M. Lee, F.H. Karzai, A. Zimmer, C.M. Annunziata, S. Lipkowitz, B. Parker, N. Houston, I. Ekwede, E.C. Kohn
Journal: Annals of Oncology (2016)
Dendritic Cell Production from Allogeneic Donor Cd34+ Stem Cells and Mononuclear Cells; Cancer Vaccine
Authors: Ali Unal, Ayse Birekul, Mehmet Cagri Unal, Esen Karakus, Yavuz Köker, Yusuf Ozkul, Faruk Metin Comu
Journal: Blood (2016)
Fever and a Pustular Rash
Authors: Christina Yek, Arjun Gupta, Melissa Mauskar
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation,
Authors: Stefano Iacovelli, Maria Rosaria Ricciardi, Paola Bergamo, Cinzia Rinaldo, Roberto Licchetta, Antonella Vitale, Anna Testi, Maria Teresa Petrucci, Marina Konopleva, Michele Milella, Robin Foà, Agostino Tafuri
Journal: Blood (2011)
An In Vivo role of Runx1 Subnuclear Targeting In Regulating the Gene Expression Program of Definitive Hematopoiesis
Authors: Christopher R Dowdy, Ronglin Xie, Dana Frederick, Sayyed K. Zaidi, Stephen N. Jones, Jane B. Lian, Andre J. van Wijnen, Janet L. Stein, Gary S. Stein
Journal: Blood (2010)
Validation of the Khorana Score in a Large Cohort of Cancer Patients with Venous Thromboembolism
Authors: Ateefa Chaudhury, Asha Balakrishnan, Christy Thai, Bjorn Holmstrom, Sowmya Nanjappa, Zhenjun Ma, Junmin Zhou, Ankita Patel, Nathan Visweshwar, Michael V. Jaglal
Journal: Blood (2016)
Low incidence of treatment-related myelodysplastic syndrome (tMDS) and acute myelogenous leukemia (tAML) in patients with non-Hodgkin's lymphoma (NHL) treated with ibritumomab tiuxetan
Authors: C. Emmanouilides, M. S. Czuczman, S. Revell, T. E. Witzig, H. Wang, L. I. Gordon, B. Skikne, P. Foster, A. Molina
Journal: Journal of Clinical Oncology (2004)

6696
First line therapy with aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas: a phase I-II study
Authors: S.P. Chawla, K. Sankhala, S. Chawla, V. Chua, E.M. Gordon, N. Chawla, K. Sung, D. Quon, K. Kim, L. Fernandez, B. Leong, S. Wieland, D. Levitt
Journal: Annals of Oncology (2016)
DDIS-09. DUAL TARGETED DELIVERY OF DOXORUBICIN TO GLIOMA CELLS USING PEGYLATED MAGNETIC GRAPHENE OXIDE
Authors: Yu Jen Lu, Pin Yi Lin, Pei Chin Yang, Ya Shu Huang, Yun Jiang, Jyh Ping Chen
Journal: Neuro-Oncology (2016)

In this study, magnetic graphene oxide (MGO) was first prepared by chemical co-precipitation of Fe3O4magnetic nanoparticles on nanographene oxide (NGO), then further modified with polyethylene glycol (PEG) and grafted with an epidermal growth factor receptor (EGFR) monoclonal antibody (cetuximab, CET). Since EGFR is highly expressed on the surface of certain glioma cells, MGO-PEG-CET could be used for dual (magnetic and ligand-mediated) targeted delivery of an anticancer drug (doxorubicin, DOX). Drug loading experiments indicated up to 325.9% (w/w) of DOX could be loaded on MGO-PEG-CET. The slow release of DOX from MGO-PEG-CET is pH sensitive, with 54.6% drug release at pH = 5.7 compared with 28% at pH = 7.4 in 7 days. The results of cell uptake studies using quantum-dots labeled nanoparticle and fluorescence imaging indicate uptakes of MGO-PEG-CET by EGFR-expressed U87MG cells is more efficient than MGO-PEG and inhibited by excess free CET, confirming facilitated endocytosis of the nanoparticle through ligand-receptor interactions. Cell cytotoxicity studies using MTT assays also showed the IC50 of MGO-PEG-CET/DOX (1.48 g/mL) is lower than that of MGO-PEG /DOX (2.64 g/mL). After combination with thermal therapy using near-infrared laser light exposure for 5 min at 2.5 W/cm2, the IC50 could be further reduced to 1.17 g/mL. In vivo anti-tumor studies with subcutaneously implanted U87MG cells in BALB/c nude mice and intravenous injection showed the relative (to day 0) tumor volumes at day 14 are 0.42 ± 0.02, 5.80 ± 1.47, 9.53 ± 0.77, 10.14 ± 1.05 and 12.13 ± 1.44 for MGO-PEG-CET/DOX + magnet + laser, MGO-PEG-CET/DOX + magnet, MGO-PEG-CET/DOX, free DOX and Normal saline, respectively. Prussian blue stain also showed increased MGO- PEG-CET accumulation in tumor sites under magnetic targeting. This synergistic targeted treatment simultaneously enhances the local drug concentration and performs the ultra-efficient tumor suppression to significantly prolong the mice survival.
EXTH-64. ECO-ONCOLOGY: APPROACHING DEVELOPMENT OF THERAPIES FOR BRAIN TUMORS FROM AN ECOLOGIST’S PERSPECTIVE
Authors: Brent Reynolds, Madan Oli
Journal: Neuro-Oncology (2016)

Conceptualizing cancer from an ecological and evolutionary perspective, where a large heterogeneous population of cells interact with their microenvironment and obey the same principles of survival and replication as those that drive Darwinian evolution, has provided a framework for understanding how fitness of neoplastic cell(s) are influenced not only by their own internal drive to survive but also by interactions with other cells and the environment (or ecology). A striking similarity can be made between a tumor population and a population of evolving species or pests. Each exhibit key defining characteristics of complex adaptive systems, where a heterogeneous collection of agents interact and communicate with each other, and alter their strategies to survive and prosper in response to the actions of the other agents and the environment. We have used this framework to devise an approach to treating high grade gliomas that incorporate principles of integrative pest management and complex adaptive systems, with the intent of controlling or managing the tumor as opposed to eliminating it. In this presentation we will highlight the key characteristics of complex adaptive systems, establish that brain tumors display these characteristics, outline the pertinent features of integrative pest management and explain how these principles can be applied to cancer therapeutics. Finally, we will present data where we have used these approaches to reduce tumor cell proliferation and tumor progression.
4E-Binding Protein 1 (4E-BP1) in CD34+ Cells as Measured by Quantitative Flow Cytometry Is an Independent Prognostic Factor in Patients with Acute Myeloid Leukemia.
Authors: M. Gorre, I. Jilani, R. Chang, J. Bareng, H. Chan, M. Keating, H. Kantarjian, E. Estey, S. O’Brien, F. Giles, M. Albitar
Journal: Blood (2005)
Incidence, Characteristics, and Outcome of FLT3-ITD Mutations in AML Arising from an Antecedent Hematologic Disorder
Authors: Tapan Kadia, Farhad Ravandi, Gautam Borthakur, Elias Jabbour, Sherry Pierce, Guillermo Garcia-Manero, Stefan Faderl, Jorge E. Cortes, Hagop M. Kantarjian
Journal: Blood (2011)
Retroperitoneal dissemination of colorectal ovarian metastases: Basis for rationale use of lymphadenectomy.
Authors: C. Eveno, D. Goárá, D. Tzanis, P. Dartigues, F. Dumont, L. Benhaim, M. Ducreux, D. Elias
Journal: Journal of Clinical Oncology (2011)

535 Background: Retroperitoneal lymph nodes are a common site of metastases in primary ovarian cancers and primary peritoneal carcinoma, therefore pelvic and paraaortic lymphadenectomy are recommended. Colorectal ovarian metastases are mostly associated to peritoneal carcionomatosis (PC), which treatment is based on complete cytoreductive surgery (CCRS) associated to intraperitoneal chemotherapy (IPC). The aim of this study was to compare the rate of nodal (pelvic, paraaortic) recurrences, between 2 groups of patients (pts) operated on PC with ovarian metastases (OM) or without OM. Methods: From January 1994 to December 2009, all consecutive women who underwent CCRS plus IPC, were selected from a prospective database. Demographics, tumor characteristics, surgical procedures and chemotherapy, were analyzed and compared. Results: One hundred and five pts were identified; 63 (60%) had ovarian metastasis (synchronous or metachronous). Groups were comparable for all variables, except for the median peritoneal cancer index which was lower in the OM group (9 vs.10.5, p&lt;.05). Nodal recurrences were diagnosed in 19 pts (18%), in paraaortic nodes in 14 pts (74%), pelvic nodes in 7 pts (36%), both in 2 pts (10%) and were associated to other relapse in 15 pts (80%). All these nodal recurrences occurred in the OM group (30% vs. 0, p&lt;.001). After a median follow-up of 74 months (10-196), 3-year overall survival rate was greater in pts without nodal recurrences (71 vs 41 %, p=0.37) and at the end of the study, there was significantly more patients died of disease in case of nodal recurrence (24/44 vs 5/19, p=.04). Conclusions: Nearly one third of patients with ovarian metastases experienced paraaortic and pelvic nodes recurrences. This may due to the specific pattern of lymphatic spread of ovary, well known in primary carcinomas. Therefore, systematic lymphadenectomy should be studied in patients with colorectal ovarian metastases treated in curative intent. No significant financial relationships to disclose.
Myeloid-derived suppressor cells (MDSCs) in metastatic castration-resistant prostate cancer (CRPC) patients (PTS)
Authors: N. Mehra, G. Seed, M. Lambros, A. Sharp, M. Sousa Fontes, M. Crespo, S. Sumanasuriya, W. Yuan, G. Boysen, R. Riisnaes, A. Calcinotto, S. Carreira, J. Goodall, Z. Zafeiriou, D. Bianchini, A. Morilla, R. Morilla, A. Alimonti, J.S. de Bono
Journal: Annals of Oncology (2016)
Intralymphocytic sodium and free calcium concentration in relation to salt sensitivity in patients with essential hypertension.
Authors: Tetsuya Oshima, Hideo Matsuura, Koji Kido, Koji Matsumoto, Tomofumi Otsuki, Hideaki Fujii, Satoko Masaoka, Mitsunori Okamoto, Yukiko Tsuchioka, Goro Kajiyama, Tokuo Tsubukura
Journal: Circulation (1987)

In order to clarify the relation between salt sensitivity and changes in intracellular sodium ([Na]i) and free calcium concentration ([Ca2+]i) after salt loading, [Na]i and [Ca2+]i were determined in lymphocytes of twenty patients with essential hypertension under a low salt diet (3 g/day) and a high salt diet (20 g/day) for seven days, respectively. They were classified as  (n=10) or  (n=10) on the basis of the changes in blood pressure after salt loading. Both lymphocytic [Na]i and [Ca2+]i were significantly increased with salt loading in salt-sensitive patients (p<0.05 for both), while they were not affected by salt loading in nonsalt-sensitive patients. Lymphocytic [Ca2+]i showed a positive correlation with lymphocytic [Na]i under both low salt diet (r=0.62, p<0.01) and high salt diet (r=0.70, p<0.01) in all patients in both groups. In addition, a close and positive correlation was observed between the changes in lymphocytic [Na]i and those in lymphocytic [Ca2+]i after salt loading in all patients in both groups (r=0.80, p<0.001). These results suggest that the increase in [Ca2+]i, possibly linked with the increase in [Na]i, may be involved in elevation of blood pressure in the salt-sensitive patients after salt loading.
Survival outcomes based on race in gastric carcinoma: A SEER database analysis.
Authors: N. Didwaniya, R. J. Edmonds, P. T. Silberstein, S. Subbiah
Journal: Journal of Clinical Oncology (2011)

5 Background: Gastric cancer is one of the leading causes of cancer related deaths worldwide with the incidence declining in the United States. However the prognosis remains poor with variable survivals being reported among different races. We analyzed the effect of race on patterns of disease presentation and survival rates using the Surveillance, Epidemiology, and End Results (SEER) database. Methods: A total of 9,851 patients were diagnosed with gastric cancer from year 2004 to 2007 were identified from SEER database. Age, race, TNM staging, grade, treatment modalities utilized and cancer specific survival was collected. Results: Out of 9,851 patients, 64.63% were white, 12.17% were black, and 13.04% were Asian-Pacific islanders. Median age was 73 years for whites, 70 years in blacks, and 71 years in Asians. Sex distribution amongst races was more or less similar with 58.83% of whites, 59.47% of blacks, and 54.24% of Asians being men. 23.62% of whites had T1 lesions, 28.10% had T2, 19.58% were T3 and 28.70% had T4 lesions. 26.76% of blacks presented with T1 lesions, 26.63% with T2, 16.08% with T3 and 30.53% with T4. 18.69% of Asians had T1 lesions, 26.84% with T2, 23.44% had T3 and 31.03% had T4 lesions. 37.80% of whites, 36.70% of blacks, and 44.44% of Asians had lymph node involvement. Tumor grade was similar among all races. Surgery was performed in 31.49% of whites, 33.13% of blacks, and 40.48% of Asians. 14.68% of whites, 14.10% of blacks, and 19.43 % of all Asians underwent radiation therapy. Median overall survival in localized disease was 44 months, 43 months and 98 months (p &lt; 0.0001) while in regional disease it was 16 months, 15 months and 23 months in whites, blacks and Asians respectively (p &lt; 0.0001). Median survival in distant disease was 4 months in both whites and blacks; it was 5 months in Asians (p &lt; 0.0001). Conclusions: Cancer-specific survival in gastric carcinoma is significantly better in localized, regional and metastatic disease in Asians when compared to whites and blacks independent of T stage, grade, nodal involvement and treatment modalities utilized. The reason for this observation is unclear, exposure and genetic factors are potential causes and this needs to be investigated. No significant financial relationships to disclose.
SURG-20. FIRST IN-HUMAN STUDY OF A NOVEL DEVICE FOR CONVECTION ENHANCED DELIVERY OF TOPOTECAN AND GADOLINIUM FOR RECURRENT GBM: INTERIM RESULTS
Authors: Michael Vogelbaum, Manmeet Ahluwalia, David Peereboom, Glen Stevens, Alireza Mohammadi, Cathy Brewer
Journal: Neuro-Oncology (2016)

The development of convection enhanced delivery (CED) as a therapeutic delivery method has been limited, in part, by a lack of technology that provides reliable, high volume infusate distribution. The Cleveland Multiport Catheter (CMC), which incorporates 4 microcatheters into a single shaft, is a novel device that was designed to produce high volume of distribution, backflow resistant CED. Two pilot trials were opened under a Sponsor-Investigator IND to evaluate the delivery of topotecan and gadolinium DTPA in patients with recurrent high grade glioma. One trial examines delivery into enhancing tumor and non-enhancing, tumor infiltrated brain, and the second evaluates delivery into tumor infiltrated brain after complete resection of the enhancing tumor. These trials have FDA and IRB approvals. Nine patients have been treated with the CMC since December, 2014. All patients underwent successful stereotactic placement of two CMCs each and completed infusions ranging from 48 to 96 hours; 3 in the first pilot trial and 6 in the second trial. Intraoperative and peri-operative MR imaging has demonstrated delivery from every CMC placed to date (18 catheters, 72 microcatheters) without obvious backflow along the CMC shaft. For the first 3 patients we found that there were approximately 10-fold differences in the volumes of distribution between catheters placed in enhancing versus nonenhancing, tumor infiltrated brain. High volume infusate distribution (range: 25 to 92 cc) was observed in the 6 patients who received 2 CMCs in tumor infiltrated brain. There were no hemorrhages related to catheter placement or removal. Infusion related safety data will be presented. This first-in-human experience shows that the CMC provides high volume, backflow resistant CED and demonstrates the value associated with use of a tracer to image infusate distribution.
Chronic Lymphocytic Leukemia-Exosomes Switch Endothelial and Mesenchymal Stromal Cells into Cancer-Associated Fibroblasts to Sustain Leukemic Cell Survival
Authors: Jerome Paggetti, Franziska Haderk, Martina Seiffert, Bassam Janji, Yeoun Jin Kim, Ute Diestler, Wim Ammerlaan, Peter Lichter, Eric Solary, Guy Berchem, Etienne Moussay
Journal: Blood (2014)
Validation of novel diagnostic kits using the semi-dry dot-blot method for detecting metastatic lymph nodes in breast cancer; distinguishing macrometastases and micrometastases
Authors: R. Otsubo, H. Hirakawa, M. Oikawa, A. Tanaka, M. Matsumoto, H. Yano, N. Kinoshita, K. Abe, J. Fukuoka, T. Nagayasu
Journal: Annals of Oncology (2016)
The Anti-Proliferative Effects of Hsp90 Inhibitor Tricyclic Coumarin GUT-70 and Geldanamycin Analog 17-DMAG in AML Cells in Hypoxia
Authors: Linhua Jin, Yoko Tabe, Kensuke Kojima, Vivian Ruvolo, Takashi Miida, Michael Andreeff, Marina Konopleva, Shinya Kimura
Journal: Blood (2011)
Comparative Global Transcriptome Analysis of Bone Marrow Stromal Cells (BMSC), Human Embryonic Stem (hES) Cells and CD34+ Cells.
Authors: Ping Jin, Jiaqiang Ren, Marianna Sabatino, Arun Balakumaran, Sergei Kuznetsov, Harvey G. Klein, Pamela G. Robey, David Stroncek
Journal: Blood (2009)